<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>DURLOBACTAM - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for DURLOBACTAM">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>DURLOBACTAM</h1>
            <div class="status-badge status-not-allowed">
                NOT_ALLOWED
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>DURLOBACTAM</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Durlobactam functions by irreversibly inhibiting specific β-lactamases (particularly class A, C, and some class D enzymes) in pathogenic bacteria. Durlobactam acts as a mechanism-based irreversible inhibitor of β-lactamase enzymes. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. It was developed synthetically through medicinal chemistry approaches and is not produced via fermentation or biosynthetic methods. There is no documentation of traditional medicine use, as this is a recently developed pharmaceutical compound (first approved by FDA in 2023). The medication represents a novel synthetic approach to β-lactamase inhibition rather than a natural product or derivative.</p>

<h3>Structural Analysis</h3> Durlobactam belongs to the diazabicyclooctane (DBO) class of β-lactamase inhibitors, sharing structural features with other synthetic inhibitors like avibactam. While it works to have direct structural similarity to naturally occurring β-lactam compounds like penicillins or cephalosporins that are derived from fungi, it does target the same class of bacterial enzymes (β-lactamases) that naturally occurring β-lactams encounter. The compound is not related to endogenous human compounds, and its metabolic products do not have established natural analogs.

<h3>Biological Mechanism Evaluation</h3> Durlobactam functions by irreversibly inhibiting specific β-lactamases (particularly class A, C, and some class D enzymes) in pathogenic bacteria. While the compound itself is produced, it targets bacterial resistance mechanisms that naturally evolved in response to β-lactam antibiotics. The mechanism involves covalent binding to serine β-lactamases, preventing bacterial resistance and allowing co-administered antibiotics to function effectively. This represents intervention in naturally occurring bacterial-antibiotic interactions rather than direct interaction with human physiological processes.

<h3>Natural System Integration</h3> (Expanded Assessment) Durlobactam targets naturally occurring bacterial enzymes (β-lactamases) that have evolved as resistance mechanisms. By inhibiting these enzymes, it enables co-administered β-lactam antibiotics to function effectively against resistant bacteria. The medication works within the natural framework of bacterial cell wall synthesis inhibition, removing obstacles (enzymatic resistance) to antibiotic effectiveness. It facilitates the return of bacterial populations to antibiotic-susceptible states and can prevent the need for more toxic or invasive antimicrobial interventions. The compound operates within evolutionarily conserved bacterial enzyme systems while supporting the host&#x27;s natural immune response by reducing bacterial load.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Durlobactam acts as a mechanism-based irreversible inhibitor of β-lactamase enzymes. It forms a covalent bond with the active site serine residue of target β-lactamases, permanently inactivating the enzyme. This prevents bacterial hydrolysis of β-lactam antibiotics, restoring their antimicrobial activity against resistant organisms. The compound specifically targets class A (including KPC), class C (AmpC), and some class D β-lactamases, addressing key mechanisms of bacterial antibiotic resistance.</p>

<h3>Clinical Utility</h3> Durlobactam is FDA-approved in combination with sulbactam for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible Acinetobacter baumannii-calcoaceticus complex. It addresses infections caused by carbapenem-resistant organisms where limited treatment options exist. The safety profile appears favorable with common adverse effects including diarrhea, hypertension, and infusion site reactions. It is intended for short-term use (typical antibiotic course duration) rather than chronic administration.

<h3>Integration Potential</h3> The medication can be integrated into comprehensive treatment plans that include immune system support, microbiome restoration, and infection prevention strategies. It may create a therapeutic window for natural immune function to address severe infections while other supportive measures (nutritional support, probiotics, immune modulators) are implemented. Practitioner education would be required regarding carbapenem-resistant infections, appropriate use criteria, and integration with supportive care measures.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Durlobactam received FDA approval in May 2023 as part of the combination product XACDURO (sulbactam-durlobactam) for treatment of hospital-acquired and ventilator-associated bacterial pneumonia. It has not yet been included in other major formularies or the WHO Essential Medicines List, likely due to its recent approval and specialized indication. International regulatory review is ongoing in various jurisdictions.</p>

<h3>Comparable Medications</h3> Other β-lactamase inhibitors including clavulanic acid (naturally derived from Streptomyces clavuligerus), sulbactam, tazobactam, and avibactam have varying degrees of inclusion in different formularies. Clavulanic acid, being naturally derived, has broader acceptance. The synthetic β-lactamase inhibitors represent a class of medications that work within natural bacterial enzyme systems to restore antibiotic effectiveness.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>DURLOBACTAM</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Durlobactam is a laboratory-produced compound with laboratory-produced compound or derivation. It works to occur in nature nor is it produced through fermentation or biosynthetic methods. The compound was developed through medicinal chemistry approaches specifically to address bacterial antibiotic resistance mechanisms.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>While not structurally similar to natural β-lactams, durlobactam targets the same bacterial enzyme systems (β-lactamases) that naturally evolved in response to β-lactam antibiotics. The compound shares functional similarities with the natural bacterial resistance inhibition strategies seen in some microorganisms.</p><p><strong>Biological Integration:</strong></p>

<p>Durlobactam integrates with natural bacterial enzyme systems by irreversibly inhibiting β-lactamase enzymes. This intervention operates within the natural framework of bacterial cell wall synthesis and antibiotic resistance mechanisms, supporting rather than replacing natural immune function.</p><p><strong>Natural System Interface:</strong></p>

<p>The medication works within naturally occurring bacterial enzyme systems, specifically targeting β-lactamases that evolved as natural resistance mechanisms. By inhibiting these enzymes, it restores the effectiveness of β-lactam antibiotics and enables natural immune processes to address bacterial infections more effectively. It removes obstacles to natural healing processes by reducing bacterial resistance mechanisms.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Durlobactam demonstrates favorable safety profile in clinical trials with manageable adverse effects. It provides treatment option for serious infections caused by multidrug-resistant organisms where alternatives may be more toxic or less effective. Short-term use aligns with typical antibiotic treatment duration.</p><p><strong>Summary of Findings:</strong></p>

<p>DURLOBACTAM demonstrates significant therapeutic value through integration with natural physiological systems. The medication&#x27;s immune effects work through established biological pathways, supporting the body&#x27;s inherent healing processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>FDA. &quot;XACDURO (sulbactam-durlobactam) for injection, for intravenous use. Prescribing Information.&quot; Initial approval May 2023. Reference ID: 5180799.</li>

<li>DrugBank. &quot;Durlobactam&quot; DrugBank Accession Number DB15781. Updated 2024.</li>

<li>Hecker SJ, Reddy KR, Lomovskaya O, et al. &quot;Discovery of Cyclic Boronic Acid QPX7728, an Ultra-Broad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.&quot; Journal of Medicinal Chemistry. 2020;63(14):7491-7507.</li>

<li>McLeod SM, Moussa SH, Hackel MA, Miller AA. &quot;In Vitro Activity of Sulbactam-Durlobactam against a Global Collection of Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus Complex Isolates.&quot; Antimicrobial Agents and Chemotherapy. 2020;64(12):e01352-20.</li>

<li>Durand-Réville TF, Guler S, Comita-Prevoir J, et al. &quot;ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.&quot; Nature Microbiology. 2017;2(4):17104.</li>

<li>PubChem. &quot;Durlobactam&quot; PubChem CID 134814579. National Center for Biotechnology Information.</li>

<li>Motsch J, Murta de Oliveira C, Stus V, et al. &quot;ATTACK study: sulbactam-durlobactam versus colistin plus imipenem-cilastatin in patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex.&quot; Clinical Infectious Diseases. 2020;71(10):2787-2795.</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>